Skip to main content

Table 1 Outcome of the evaluated parameters during twelve months of anticoagulant treatment with warfarin and rivaroxaban in the patients with paroxysmal nocturnal haemoglobinuria

From: Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events

 

W

R

W

R

W

R

 

Pt 1: Female, 45 yrs.

Pt 2: Female, 66 yrs.

Pt 3: Female, 45 yrs.

Thrombosis of superior sagittal sinus

Thrombosis of portal vein

Deep vein thrombosis

Haemoglobin (gr/dL)

7. 7± 0.4

8.4 ± 0.6

0.006

12.5 ± 0.6

13.1 ± 0.2

n. s.

7.9 ± 0.5

7.8 ± 0.6

n. s.

Haematocrit (%)

22.9 ± 2

25.4 ± 1.4

0.003

38.5 ± 1.4

39.4 ± 0.7

n. s.

27.8 ± 1.6

28.6 ± 2.8

n. s.

Platelets (×  103/μL)

81.9 ± 9.4

73.8 ± 10.3

n. s.

118.1 ± 24.2

112.3 ± 6.7

n. s.

357.2 ± 27.2

347.3 ± 28.8

n. s.

Lactate deydrogenase (IU/L)

326.7 ± 15.0

311.7 ± 11.4

n. s.

249.1 ± 44.4

257.3 ± 40.1

n. s.

331.6 ± 207.3

312.8 ± 177.3

n. s.

Bleeding Days

6.0 ± 0.8

3.6 ± 0.7

0.001

      

Low Molecular Weight Heparin (Days of bridging-therapy)

8.2 ± 0.7

1.7 ± 1.1

< 0.001

      

Red Blood Cell Units transfused

11

4

0.03

0

0

 

6

6

 

Diapers (number)

14.9 ± 0.6

10 ± 0.8

< 0.001

      

Hospital admissions (Days per month)

4.2 ± 0.7

2.7 ± 0.8

< 0.001

3.7 ± 0.6

2.8 ± 0.6

0.001

4.0 ± 0.7

2.6 ± 0.8

0.001

 

Pt 4: Male, 27 yrs.

Pt 5: Female, 54 yrs.

All patients

Thrombosis of portal vein

Thrombosis of caval vein

Haemoglobin (gr/dL)

13.3 ± 0.6

13.6 ± 0.9

n. s.

10.9 ± 0.3

10.5 ± 0.2

n. s.

9.9 ± 2.5

9.8 ± 2.4

n. s.

Haematocrit (%)

39.9 ± 1.9

39.3 ± 3.3

n. s.

33.7 ± 1.4

31.0 ± 1.0

n. s.

31.4 ± 7.0

30.5 ± 5.7

n. s.

Platelets (× 103/μL)

94.3 ± 9.9

94.4 ± 11.5

n. s.

186.7 ± 23.9

192.5 ± 13.9

n. s.

186.3 ± 120.5

191.9 ± 123.0

n. s.

Lactate deydrogenase (IU/L)

228 ± 28.1

200.7 ± 21.4

n. s.

310.3 ± 57.4

272.0 ± 6.0

n. s.

285.9 ± 107.3

274.4 ±100.0

n. s.

Bleeding Days

         

Low Molecular Weight Heparin (Days of bridging-therapy)

         

Red Blood Cell Units transfused

0

0

 

0

0

 

17

10

n. s.

Diapers (number)

         

Hospital admissions (Days per month)

3.5 ± 0.5

2.2 ± 0.4

0.001

3.1 ± 0.5

2.2 ± 0.6

< 0.001

3.7 ± 0.7

2.5 ± 0.7

< 0.001

  1. Reported data are the mean values and standard deviations of the evaluated parameters performed every month for twelve months during the treatment with warfarin (W) and rivaroxaban (R)
  2. Statistical analysis was performed using Student’s t-test. Significant level was set to p < 0.05. n. s. = not significant
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us